JP2010504088A5 - - Google Patents

Download PDF

Info

Publication number
JP2010504088A5
JP2010504088A5 JP2009528732A JP2009528732A JP2010504088A5 JP 2010504088 A5 JP2010504088 A5 JP 2010504088A5 JP 2009528732 A JP2009528732 A JP 2009528732A JP 2009528732 A JP2009528732 A JP 2009528732A JP 2010504088 A5 JP2010504088 A5 JP 2010504088A5
Authority
JP
Japan
Prior art keywords
seq
mature protein
nucleic acid
disease
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009528732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504088A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/060013 external-priority patent/WO2008034891A2/en
Publication of JP2010504088A publication Critical patent/JP2010504088A/ja
Publication of JP2010504088A5 publication Critical patent/JP2010504088A5/ja
Pending legal-status Critical Current

Links

JP2009528732A 2006-09-21 2007-09-21 グルタミニルシクラーゼに関連した新規遺伝子 Pending JP2010504088A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84624406P 2006-09-21 2006-09-21
US94778007P 2007-07-03 2007-07-03
PCT/EP2007/060013 WO2008034891A2 (en) 2006-09-21 2007-09-21 Novel genes related to glutaminyl cyclase

Publications (2)

Publication Number Publication Date
JP2010504088A JP2010504088A (ja) 2010-02-12
JP2010504088A5 true JP2010504088A5 (enExample) 2010-11-11

Family

ID=38779576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009528732A Pending JP2010504088A (ja) 2006-09-21 2007-09-21 グルタミニルシクラーゼに関連した新規遺伝子

Country Status (12)

Country Link
US (3) US20080249083A1 (enExample)
EP (2) EP2082041B1 (enExample)
JP (1) JP2010504088A (enExample)
KR (1) KR101432848B1 (enExample)
AU (1) AU2007298929B2 (enExample)
BR (1) BRPI0718507A2 (enExample)
CA (1) CA2663635A1 (enExample)
EA (1) EA016584B1 (enExample)
IL (2) IL197090A (enExample)
MX (1) MX2009003090A (enExample)
NZ (2) NZ575727A (enExample)
WO (1) WO2008034891A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060009902A (ko) * 2003-05-05 2006-02-01 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
US9277737B2 (en) 2006-09-21 2016-03-08 Probiodrug Ag Mouse models carrying a knock-out mutation of the QPCTL-gene
US8889709B2 (en) 2006-09-21 2014-11-18 Probiodrug Ag Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions
WO2008034891A2 (en) 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase
US8420684B2 (en) * 2006-11-09 2013-04-16 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5599614B2 (ja) * 2006-11-09 2014-10-01 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
US8278345B2 (en) * 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) * 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2395095A1 (en) * 2007-01-19 2011-12-14 Probiodrug AG In vivo screening models for treatment of Alzheimer's disease and other QPCT-related disorders
WO2008110523A1 (en) * 2007-03-09 2008-09-18 Probiodrug Ag Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
WO2008128985A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
JP5675341B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体
EP2160380B1 (en) * 2007-04-18 2014-04-02 Probiodrug AG Cyano-guanidine derivatives as glutaminyl cyclase inhibitors
ES2468551T3 (es) * 2007-04-18 2014-06-16 Probiodrug Ag Derivados de nitrovinil-diamina como inhibidores de la glutaminil ciclasa
EP2142515B1 (en) * 2007-04-18 2014-03-26 Probiodrug AG Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
JP5675343B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
JP5676249B2 (ja) * 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
AU2008297070A1 (en) * 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
WO2009090190A1 (en) * 2008-01-14 2009-07-23 Probiodrug Ag Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
EA025107B1 (ru) * 2008-07-31 2016-11-30 Пробиодруг Аг Способ диагностирования болезни альцгеймера, нейродегенерации при синдроме дауна или легкого когнитивного нарушения у субъекта (варианты) и набор для осуществления способа
MX2011002106A (es) * 2008-09-04 2011-04-07 Probiodrug Ag Inhibidores novedosos.
EP2344158B1 (en) * 2008-09-04 2017-12-27 Probiodrug AG Use of isoqc inhibitors
WO2010133620A2 (en) * 2009-05-19 2010-11-25 Probiodrug Ag Mouse models carrying a knock-out mutation of the qpctl-gene
EP2537029A1 (en) * 2010-02-18 2012-12-26 Probiodrug AG Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
ES2540467T3 (es) 2010-08-19 2015-07-09 Probiodrug Ag Estructura cristalina de glutaminil ciclasa
JP2013541938A (ja) 2010-09-02 2013-11-21 プロビオドルグ エージー アイソｑｃ関連障害の治療のためのインビボスクリーニングモデル
US8741614B2 (en) 2010-11-02 2014-06-03 Probiodrug Ag Crystal structure of isoglutaminyl cyclase
WO2014015157A2 (en) 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
US20180318260A1 (en) * 2015-11-04 2018-11-08 The Scripps Research Institute Compositions and methods for treating cystic fibrosis
WO2019022600A1 (en) * 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases
GB201918108D0 (en) * 2019-12-10 2020-01-22 Vib Vzw Improved aminopeptiadases for single molecule peptide sequencing
WO2025224179A1 (en) 2024-04-23 2025-10-30 Vivoryon Therapeutics N.V. Glutaminyl cyclase inhbitors for use in the treatment of kidney disease
WO2025224169A1 (en) 2024-04-23 2025-10-30 Vivoryon Therapeutics N.V. Dose regimens for the glutaminyl cyclase inhibitor varoglutamstat

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IT1183575B (it) 1985-05-08 1987-10-22 Eurand Spa Formulazione deodorando ad effetto modulante sulla trfaspirazione
DD293584A5 (de) 1990-03-23 1991-09-05 Adw,Zi Fuer Organische Chemie,De Verfahren zur herstellung von neuen 3,5,5-trisubstituierten 1-(benzimidazol-2-yl)-imidazolidin-2,4-dionen bzw. -4-on-2-thionen
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6247293B1 (en) * 1998-11-03 2001-06-19 Klockner Bartelt, Inc. Modular packaging machine with web tension control
FR2796945B1 (fr) 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
FR2808711B1 (fr) * 2000-05-10 2002-08-09 Poudres & Explosifs Ste Nale Procede de fabrication d'elements composites etain-tungstene de faible epaisseur
WO2002093436A1 (en) * 2001-05-11 2002-11-21 Swisscom Mobile Ag Method for transmitting an anonymous request from a consumer to a content or service provider through a telecommunication network
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
KR100474689B1 (ko) * 2001-08-30 2005-03-08 삼성전자주식회사 이동통신 시스템에서 소프트 핸드오프 도중의 전력제어 방법
AU2002359474A1 (en) * 2001-11-26 2003-06-10 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7677859B2 (en) 2002-07-22 2010-03-16 Brooks Automation, Inc. Substrate loading and uploading station with buffer
GB0220501D0 (en) * 2002-09-04 2002-10-09 Hall Geoffrey W Push 22
US20040098591A1 (en) * 2002-11-15 2004-05-20 Fahrny James W. Secure hardware device authentication method
US6851324B2 (en) * 2002-12-16 2005-02-08 Delphi Technologies, Inc. Non-contacting compliant torque sensor
KR20060009902A (ko) * 2003-05-05 2006-02-01 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8338120B2 (en) * 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
EP1620091B1 (en) * 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
PL1620082T3 (pl) * 2003-05-05 2010-10-29 Probiodrug Ag Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa
US7192995B2 (en) * 2003-10-03 2007-03-20 Virginia Commonwealth University Homogenous compositions of polymers and crystalline solids or cross-linking agents and methods of making the same
AU2004283461B2 (en) * 2003-10-15 2010-02-11 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US7667044B2 (en) * 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2004290499C1 (en) * 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
MXPA06005742A (es) * 2003-11-19 2006-12-14 Acrux Dds Pty Ltd Metodo y composicion para el tratamiento de lesiones cutaneas.
WO2005075436A2 (en) * 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US20080299042A1 (en) * 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
WO2006014153A1 (en) * 2004-07-01 2006-02-09 Micro Motion, Inc. Split balance weights for eliminating density effect on flow
US7663268B2 (en) * 2006-08-30 2010-02-16 The Regents of the University of Cailfornia Converters for high power applications
WO2008034891A2 (en) * 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase
ES2468546T3 (es) 2006-11-09 2014-06-16 Probiodrug Ag Nuevos inhibidores de glutaminil ciclasa
JP5676249B2 (ja) * 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体

Similar Documents

Publication Publication Date Title
JP2012500993A (ja) 潰瘍性大腸炎及び関連した疾患における抗ｔｎｆ処置のためのバイオマーカー
JP2012115275A5 (enExample)
CA2734519C (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
WO2016077366A1 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
JP2006081548A5 (enExample)
JP2009039107A5 (enExample)
RU2009135270A (ru) Способы выявления воспалительного заболевания кишечника
US7645582B2 (en) Aptamers that bind to listeria surface proteins
JP4969638B2 (ja) 単球由来核酸および関連する組成物ならびに方法
JP2003524415A5 (enExample)
US20080102458A1 (en) Polymorphic loci that differentiate escherichia coli 0157:H7 from other strains
EP1470240A2 (en) Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747,1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165,2
US20100092468A1 (en) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
WO2001012664A2 (en) Notch receptor ligands and uses thereof
JP2004500117A5 (enExample)
KR100976005B1 (ko) 만성 류마티스관절염 질환 감수성 유전자, 이의 단백질,이들을 이용한 만성 류마티스관절염의 발증가능성의 판정방법 및 판정 키트, 및 만성 류마티스관절염의 치료 방법및 치료 약제
JP2009523004A5 (enExample)
CN104372009A (zh) 梅尔克松-罗森塔尔综合征新的致病基因及其编码蛋白质和应用
CN120866510A (zh) 巨噬细胞刺激1受体(mst1r)变体及其用途
EP1401497A1 (en) Methods for the modulation of il-13
CN101294197A (zh) 冠心病检测方法和试剂盒
CN101525658A (zh) 强直性脊柱炎易感性检测方法和试剂盒
WO2004042052A1 (en) Modulating tnf (alpha) secretion
WO2001098456A2 (en) IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
CN115315527A (zh) 用于治疗il33中存在风险等位基因的受试者的治疗方法